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D B S/M icrobiology

Isolation an d Identification of Inhibitory Factor(s) of L eukotriene D* D ip ep tid ase
in H um an Serum
(58 pp)
Director: G eo rg e L. Card
LTD d ip ep tid a se is th e e n z y m e that con verts th e m ost active leukotriene,
LTD4, to th e lea st activ e form, LTE4. T he biological activity of LTD4 h a s b e e n
reported to b e se v e r a l tim es higher than that of LTE4. T herefore, th e nature
a n d intensity of a leukotriene r e sp o n se could b e in flu enced by th e relative
con cen tration of LTD4 and LTE4, which in turn, cou ld b e determ ined by th e
relative rate of m etab olism of LTD4 to LTE4. In undiluted, untreated hum an
seru m , inhibition of LTD d ip ep tid ase w a s o b se rv ed . T h e sp e cific activity of
LTD d ip ep tid a se in c re a se d on dilution of hum an seru m . T o iso la te an d identify
inhibitory factor(s), s iz e ex clu sion chrom atographic te c h n iq u e s w ere em p lo y ed .
T h e inhibitory factor(s) w a s sep a ra ted from the seru m d ip ep tid a se by
ultrafiltration with A m icon YM -10 m em b ran es. T he inhibitory activity in th e YM10 filtrate w a s sta b le on prolonged (over 3 0 m inutes) h eating at 95® C, sta b le in
0 .3 M N aO H , and w a s d estro y ed by acid treatm ent at 0® 0 and 30® 0 .
Ultrafiltration with YM -10, YM-3, YM- , and Y C -05 m em b ra n es s u g g e s t e d that
th e m olecu lar w eigh t of th e inhibitor(s) w a s le s s than 5 0 0 . B a s e d on t h e s e
o b se r v a tio n s and th e elution volum e of th e inhibitor activity from a P -2 gel
filtration colum n, th e inhibitor h a s b e e n tentatively identified a s carb on ate
(b icarbon ate). T h e LTD4 d ip ep tid ase activity in a 50-75% am m onium sulfate
sa tu ra ted fraction of seru m w a s inhibited by carb on ate (bicarbonate) or
p h o sp h a te , but not by nitrate, sulfate an d chloride. A m axim um of 50%
inhibition of d ip ep tid a se activity w a s o b se rv ed at 2 5 0 mM bicarbon ate.
C om p arab le co n cen tra tio n s of p h osp h ate result in 100% inhibition. T he
p h y siological inhibitor in serum a p p ea red to b e carb on ate (bicarbonate). T he
relative carb on ate (bicarbonate) concentration could b e a factor in determ ining
th e rate of LTD to LTE con version , and therefore important in m odulating the
leukotriene m ed iated r e sp o n se .
4

4

4

1

4

4

1 1

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ACKNOWLEDGMENT
I w ant to thank th e S tella Duncan Memorial Foundation for th e funding of
th is re sea rch . I w ant a lso to thank my graduate com m ittee m em b ers for their
patient g u id a n ce and valu ab le critique throughout my grad u ate resea rch an d
t h e s is writing.
T h an k s are a lso d u e to S . Miller, J. R eim ers, and M. R h od s for their
e x c e lle n t tech n ica l a s s is ta n c e , to Dr. J. N akam ura and Dr. G. G u sta fso n for
their invaluable en co u ra g e m e n t and help throughout m y grad u ate stu dy at DM.
S p ecia lly , I w ould like to thank my b e st friends K. A lbe, B. Mitchell an d D. P an g
for th e everything th ey h a v e d o n e for m e.
My d e e p e s t appreciation g o e s to tw o great p rofessors: B. Wright an d G.
Card. Not only h a v e I learned from them how to d o scientific resea rch , but a lso
h ow to d o great wind surfing.
I w ould like a lso to thank my uncle in Hong Kong for his g e n e r o u s
financial support, my sister, Audrey, and my d ear girlfriend, H ong, for their love,
ca r e, en co u ra g em en t.
Finally, I w ould like to p resen t this work to my mum, th e g re a te st m other
in th e world, for her m any y e a r s con stan t en co u ra g em en t, ed u ca tin g , ca r e , an d
love.

Ill

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

TABLE OF CONTENTS
P age
A B ST R A C T ...................................................................................................ii
ACKNOW LEDGMENT

..............................................................iii

LIST OF F IG U R E S .................................................................................. v
LIST OF T A B L E S ..................................................................................... v ü
CHAPTER
1. INTRODUCTION.................................................................... 1
2 . MATERIALS AND M ETH O D S........................................... 14

3. R E S U L T S ...................................................................................19
4. D ISC U SSIO N ............................................................................40
5. SUM M ARY................................................................................ 51
LITERATURE C IT E D .............................................................................53

IV

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

LIST OF FIGURES
F ig u re

P age

1.

T he M etabolism o f A rachidonic A c id ...................................... 2

2.

T he R elease o f A rachidonic A c id ............................................. 3

3.

5-L ipooxygenase P a th w a y ................................................... ......7

4.

P ep tid y l L eukotriene M eta b o lism ........................................... 10

5.

Serum LTD^ D ipeptidase D ilution S t u d y .............................. 20

6.

F iltered Serum LTD^ D ipeptidase A ctivity S t u d y ............. 21

7.

A m m onium Sulfate F ractionation o f S e r u m ........................ 22

8.

M etabolism o f LTE^ to U nknow n M e ta b o lite .......................23

9.

T im e C ourse Study o f LTD^ D ip e p tid a se ............................... 25

10 . D ifferen t C ations Effects on D ip e p tid a s e ..............................26
11 . T he Influence o f NaCl C oncentration o n LTD^

D ip ep tid ase A c tiv ity .....................................................................27
12. The Influence o f CaCl^ C oncentration on LTD^
D ip ep tid ase A c tiv ity .....................................................................28
13. O ptim al C ondition for D ipeptidase A c tiv ity ........................ 29
14. S ep aration o f LTD^ D ipeptidase Inhibitor by
Bio-R ad G el P-2 C o lu m n ..............................................................31
15. C om parison o f R eten tion Tim e o f B icarbonate and
LTD 4 D ip ep tid ase Inhibitor From S e r u m ..............................32
16. D eterm in ation o f the M olecular W eight o f LTD^
D ip ep tid a se I n h ib ito r ...................................................................35
17. A cid T reatm ent o f I n h ib ito r

...............................................36

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

F igu re

P age

18. D ifferent A nions Effects on D ip e p tid a s e ................................37
19. In h ib ition o f D ipeptidase by B ic a r b o n a te .............................38
20. Inhib ition o f D ipeptidase by P h o s p h a te ................................39

VI

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

LIST OF TABLES
T able

P age

1. The D ipeptidase Inhibition P rop erties o f YM-10
F ilt r a t e ............................................................................................... 30
2. C om parison o f th e LTD4 D ip ep tidase S en sitiv ity to
B esta tin and C ila sta tin .................................................................42

Vll

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER 1
INTRODUCTION
Arachidonic acid (5,8,11,14-eicosatetraenoic acid) is a 20-carbon
polyunsaturated fatty acid. It is commonly present in cell membrane
phospholipid (phosphatidylcholine, phosphatidyl-inositol, etc.) esterified
prim arily to the second carbon (C-2) position of glycerol. Release of
arachidonic acid from the lipid pool by the action of phospholipase A^ is
m ediated by different types of stimuli (57), which can be physiological or
pathological. The released arachidonic acid has a very short half life. It is
eith er metabolized by the enzyme, cyclooxygenase, to form prostaglandins
and thromboxanes, or by lipoxygenase pathways to form leukotrienes and
lipoxins (57), or is reincorporated into the membrane lipids (Fig. 1).
Arachidonic acid is derived primarily from two phosphlipids,
phosphatidylinositol and phosphatidylcholine. Two enzymes, phospholipase
C and phospholipase Ag are mainly involved in the release of arachidonic
acid (Fig. 2). When cells are activated by stimuli, it leads to the increased
perm eability of ions across the membrane, especially a flow of

ions

from the extracellular to intracellular compartment. The resulting
increased intracellular Ca+ concentration stim ulates the cytoplasmic
phosphatidylinositol specific phospholipase C, which acts on
phosphatidylinositol to give inositoltriphosphate (IP3) and
diacylglyceride (DAG) (57). DAG is acted upon by other lipases to yield a
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Figure 1. The metabolism of arachidonic acid
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monoacylglyceride and arachidonic acid. IP induces additional Ca^*
3

mobilization from the endoplasmic reticulum to the cytoplasm, and this
fu rth er activates phospholipase C. Protein kinase C (PKC) is the major
enzyme activated by DAG. PKC phosphorylates a phospholipase Aj
inhibitory protein. This phosphorylation causes inactivation of the
inhibitory protein, resulting in increased activity of phospholipase Ag,
which cleaves arachidonic acid from phosphatidylcholine ( ).
1

The formation of prostaglandins and thromboxanes is initiated by the
enzyme prostaglandin endoperoxide synthase (PES). The cyclooxygenase
activity of the prostaglandin endoperoxide synthase can transform
arachidonic acid and certain other polyunsaturated fatty acids into
prostaglandins. The enzyme oxidizes arachidonic acid to yield a 15hydroperoxy-9,1 -endoperoxide with a substituted cyclopentane ring (PGGj).
1

The peroxidase activity of PES then reduces PGGg to its 15-hydroxy
analogue (PGHg). The cyclooxgenase and peroxidase activities of PES reside
in a single protein (51). PGHg can be converted into PGDg, PGEg, PGFg, and
PGIg by the enzymes glutathione-S-transferase, prostaglandin endoperoxide
E isomerase, prostaglandin endoperoxide reductase and prostaglandin
endoperoxide I isomerase, respectively.
The formation of thromboxane Ag is catalyzed by thromboxane A
synthase. The enzyme th a t converts prostaglandin endoperoxides to
thromboxanes was first found in platelets (51). The physiological effects of

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

prostaglandins and thromboxanes have been studied in great detail. They
affect nearly every system in the body and include inflammation, clotting,
osmotic gradients and smooth muscle contraction.
The lipoxygenase pathways involve insertion of oxygen molecules a t
5-, 12-, and 15- carbon positions of arachidonic acid by 5-, 12-, and 15lipoxygenases, respectively. The platelet 12-lipoxygenase converts
arachidonic acid to 12-S-hydroperoxyeicosa-5,8,10,14-tetraenoic a d d (12-SHPETE). Peroxidase activity associated with the 12-lipoxygenase
hydrolyzes 12-HPETE into its hydroxy analogue 12-HETE. The biological
activities of the

1

2

-lipoxygenase products include the migration of aortic

smooth muscle cells in vitro, inhibition of collagen-induced platelet
aggregation, inhibition of cyclooxygenase activity at high concentration, and
the amplification of the production of LTB* (50).
The 15-lipoxygenase converts arachidonic acid to 15-hydroperoxide
eicosatetraenoic a d d (15-HPETE) and this product inactivates the enzyme
by oxidizing a single methionine residue (44). At least two trihydroxylated
compounds, lipoxin A (5,6,15(L)-trihydroxy-eicosa-7,9,ll,13-tetraenoic add)
and lipoxin B (5(0),14,15 {L)-trihydroxy-eicosa-6,8,10,12-tetraenoic acid), are
formed when hum an neutrophils are incubated with 15-HPETE and a
caldum ionophore. These lipoxins are another group of biologically active
derivatives which can cause contraction of lung strips, dilation of
microvasculature, and inhibition of natural killer cell cytotoxicity. They

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

m ay also play an im portant role in inflammation and im munity (49).
The leukotriene family is a group of biologically active molecules,
formed by leukocytes, m ast cells, macrophages, and other tissues and cells
in response to immunological and nonimmunological stimuli. They were
first reported in 1938 as a smooth muscle-contracting factor in lung
perfusates and referred to as "slow reacting substance of anaphylaxis" (SRSA). I t was not until 1979 th a t their structures were identified and their
physiological functions elucidated.
The enzyme 5-lipoxygenase catalyzes the lipoxygenation of
arachidonic acid a t C-5 to initiate the synthesis of leukotrienes (23) (Fig. 3).
Leukotriene A (LTA*) is a key interm ediate in leukotriene biosynthesis. It
4

is derived from arachidonic acid by two consecutive reactions, oxygenation
a t C-5 followed by dehydration, both catalyzed by -lipoxygenase. The
6

highly unstable allylic epoxide LTA can be metabolized by two alternative
4

pathways. Hydrolysis of LTA , catalyzed by LTA hydrolase leads to the
4

4

formation of leukotriene B (LTB ) (50). LTB can be further metabolized by
4

4

4

CD-hydroxydation to 20-hydroxy and 20-carboxy LTB (7). Alternatively, the
4

addition of glutathione by a glutathione transferase leads to the peptidyl
leukotriene, leukotriene C (LTC ) (3, 43). LTC can be cleaved successively
4

4

4

by peptidase enzymes to yield leukotrienes D (LTD ) and LTE4.
4

4

The cysteinyl-containing leukotrienes (LTC4, LTD4, and LTE4) are
potent bronchoconstrictors. They increase permeability in postcapillary venules
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Figure 3. 5-lipooxygenase pathway
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and stim ulate mucus secretion (14, 43, 49). The dihydroxy derivative, LTB ,
4

which is a calcium ionophore, causes adhesion and chemotactic movement of
leukocytes and stim ulates aggregation, enzyme release, and generation of
superoxide in neutrophils (43). LTC^, LTD^, and LTE4, which are released
from lung tissues of asthm atic subjects on exposure to specific allergens,
seem to play a pathophysiological role in immediate hypersensitivity
reactions (54). All of the leukotrienes have proinflammatory effects (47).
Leukotrienes are also formed in the central nervous system (50). The
highest production of LTC4 is found in hypothalamus and the median
eminence. Immunohistochemical studies revealed the coexistence of LTC

4

and luteinizing hormone-releasing hormone (LHRH) in neurons in the
m edian eminence. Furtherm ore, LTC caused release of luteinizing
4

hormone (LH) from ra t anterior pituitary cells suggesting a neuroendocrine
role of LTC4.
Several other functions of LTs have been identified recently.
Investigations by Quinn et al. showed LTC , LTD and LTE played a role
4

4

4

as mediators of delayed onset acute lung injury after smoke inhalation (42).
It was also reported th a t leukotrienes contributed to the persistence of a
hydrochloric acid induced gastric lesion (39). Leikaut and his colleagues
found th a t cysteinyl leukotrienes enhanced growth of airway epithelial cells
which suggested a new physiological role for the leukotrienes in the lung
th a t links inflammation with epithelial cell proliferation (32). It was also

8
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reported th a t LTC decreased the activity of respiratory cilia in vitro (61).
4

LTC is converted to LTD by cleavage of the glutamic acid residue by
4

4

a y-transpeptidase (Fig. 4). This enzyme has been found in ra t basophil
leukemia cells (25), in the supernatant of PMNs ( , 45), in hum an plasm a
6

(28) and lung (29), and in guinea pig lung tissue. The study of the
transpeptidase in hum an serum in our lab and other laboratories showed
th a t the metabolism of LTC4 into LTD4 was dependent on time, am ount of
enzyme present and on the substrate concentration (60). Several forms of
the serum y-glutamyl transpeptidase have been reported and have been
described as isoenzymes or modifications of a single gene product.
Cleavage of a glycine residue from LTD4 by dipeptidase activity
results in the formation of LTE4. The relative activity of the ytranspeptidase and the LTD dipeptidase m ight have im portant
4

physiological consequences. The dipeptidase catalyzes the conversion of the
m ost active peptidyl leukotriene, LTD4, to the least active peptidyl
leukotriene, LTE4. The pioneering work on dipeptidase was done by
Campbell who first purified a porcine renal dipeptidase (9). Dipeptidase
enzymes have been subsequently isolated from many different tissues and
cells including: rat, hog (9), hum an (11), and monkey kidneys, sheep (10),
ra t (22), hum an (29), and guinea-pig lungs, ra t liver (24), ra t basophil
leukem ia cells (25), hum an PMNs (36, 45, 46), and hum an serum (28, 60).
Time course studies showed a relatively slow conversion of LTD4 to LTE4,
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compared to the rate of conversion of LTC to LTD (28). Dipeptidase is
4

4

usually found as a membrane bound enzyme. Recently, Campbell and his
coworkers (

1

0

) showed th a t the protein is anchored to the lipid bilayer by a

covalent attachm ent to phosphatidylinositol via a C-terminal glycolipid
extension. The dipeptidase was released by the treatm ent of
phosphatidylinositol-specific phospholipase C from Bacillus thuringiensis.
Size exclusion chromatography (SEC)-HPLC and electrophoresis analysis
showed the molecular weight of the enzyme is between 105,000-140,000
daltons. The enzyme is composed by two monomers of molecular weight
50,000 to 70,000 daltons (10). The optimal reaction condition for the
dipeptidase activity was obtained with

1

mM of Mn^^, Co^^, or Zn^^ (44, 36),

and was completely inhibited by Cu^"^ (44), bestatin (11, 40) and a renal
dipeptidase inhibitor, cilastatin (MK0791) (27). The presence of a natural
inhibitory effect of LTD conversion has been mentioned briefly by Raulf
4

and coworkers (45, 46). Studies in our lab have suggested some type of
in h ib ito rs) is present in hum an serum (60). The LTD dipeptidase activity
4

in hum an serum appeared to be regulated by the am ount of the inhibitors)
ra th e r th an the am ount of enzyme. This indicates th a t the inhibitors) in
hum an serum may play a very im portant role in regulating the leukotriene
levels in hum an circulation under different physiological and pathological
conditions (60).
F u rth er metabolism of LTE has been reported in several tissues.
4

11
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B ernstrom and his colleagues (5) reported th a t ra t liver homogenates can
covert LTE to acetyl-LTE^, with the acetyl group from acetyl coenzyme A.
4

Acetyl-LTE^ was the major metabolite recovered in the bile (21). It was also
found th a t the hum an and ra t kidneys convert the LTE^ to acetyl-LTE^
which was then found in the urine. LTA can also undergo nonenzymatic
4

hydrolysis into the C-12 epimers of, 12-dihydroxy-6,8,10-trans-14-ciseicosatetraenoic acid and two isomers of 5,6-dihydroxy-7,9,11,14eicosatetraenoic acid (

2

0

).

Although the biological effects of LTE and acetyl-LTE are 100-fold
4

4

lower th an th at of LTD , they still have biological activity (48). So, the
4

fu rth er metabolism of LTE* and acetyl-LTE resulting in complete
4

term ination of the biological activity has been extensively examined (4).
More recently, Shamhoun and his coworkers showed another route of
degradation of LTE and acetyl-LTE via co-oxidation and p-oxidation which
4

4

alters the fatty acid (16, 48). The end products formed here were 20-COOHLTE , 20-COOH-N-acetyl LTE , 18-COOH-19,20-dinor-LTE4 (dinor-LTE ),
4

4

4

and 16-COOH-17,18,19,20-tetranor-LTE4 (tetranor-LTE ). These results
4

dem onstrate th a t the metabolism of leukotrienes may be a detoxification
ra th e r th an an inactivation of cysteinyl-containing leukotrienes.

12

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

TH ESIS OBJECTIVE;

The major objectives of this study were to isolate, characterize, and
hopefully identify the factor(s) which inhibits LTD^ dipeptidase activity in
hu m an serum.

13
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CHAPTER 2
MATERIALS AND METHODS

M aterials:
HPLC Grade methanol and acetonitrile were purchased from Fisher
Chemical, Fisher Scientific (Fair Lawn, NJ).

Leukotrienes were purchased

from Cayman Chemical (Ann Arbor, MI), and the tritium labelled
leukotrienes were purchased from New England Nuclear (Boston, MA). The
resin, nucleosil 5 C18 lOOA, for reverse phase HPLC was obtained from
Phenomenex (Torrance, CA), and the columns were generously packed by
ChromatoChem, Inc. (Missoula, MT). YM m embranes were purchased from
Amicon Div., W.R. Grace & Co. (Danvers, MA). The Bio-Gel P-2 was firom
Bio-Rad Laboratories (Richmond, CA). The bicinchoninic acid protein assay
reagents were purchased from Sigma Chemicals (St. Louis, Mo). All other
chemicals were of reagent grade and purchased from standard sources.

Methods:
1

. Collection of Hum an Blood and Sera:
H um an blood from healthy volunteers was drawn from the cubital vein

into heparinized or heparin-free vacutainers. The blood was set in the 30° C
w ater bath for 30 min until the clotting was completed, and was centrifuged
a t 2,000 rpm, a t 4° C, for 30 min. The serum was collected using a Ulti-Sep

14
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Serum Separator, and pooled. The pooled sera was divided into

1

ml

aliquots and stored a t -70° C.

2. Separation of LTD Dipeptidase from the Inhibitory F actors)
4

Serum was mixed with 20 mM Tris-HCl buffer (pH 7.4) in a 1:50 ratio
and filtered with an Amicon Micro-ultrafiltration system using a YM-10
membrane. The flow rate was 10 ml per hour under 40 psi nitrogen a t 5° C.
The filtered serum was divided into

1

ml aliquots and stored a t -70° C.

3. Ammonium Sulfate Fractionation of LTD^ Dipeptidase:
The method developed by B. J. Campbell (9) was modified and used. In a
typical preparation, 3 grams solid ammonium sulfate were added to 10 ml of
pooled sera, mixed and allowed to stand a t 4° C for 12 hours. The 50%
ammonium sulfate saturated sera was then centrifuged a t 4,500xg for 1
hour. The pellet was resuspended in 5 ml 20 mM Tris-HCl Buffer at pH 7.4
and dialyzed against the same buffer for 18 hours with four changes of
buffer. Solid ammonium sulfate was then added to the supernatant to
result in 75% saturation. After standing a t 4° C over night, the 75%
ammonia sulfate saturated suspension was centrifuged a t

1

0

,

0

0

0

xg for

1

hour. The sediment was resuspended in 5 ml 20 mM Tris-HCl buffer at pH
7.4 and dialyzed as previously described. The two different fractions will be
designated as 50% precipitate and 75% precipitate.

15
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4. Isolation and Concentration of Inhibitor by Ultrafiltration:
In a typical experiment, 50 ml pooled sera was added to an Amicon
ultrafiltration system model 52 with a YM-10 membrane, under 40 psi
nitrogen a t 4" C. The filtrates from several runs (about 40 ml) were pooled,
divided to 20 ml aliquots and lyophilized. The lyophilized filtrate was
resuspended in 1 ml triple distilled w ater and was designated as 20X
concentrated inhibitor solution.

5. Purification of Inhibitor by Gel Filtration:
Size Exclusion Chromatography (SEC) was used to attem pt to further
isolate the inhibitor. The Bio-Rad polyacrylamide gel resin P-2 was used.
Best resolution was obtained with a 1.3 X 45 cm column using an eluent
buffer containing 10 mM Mops and 10 mM NaCl, pH 7.4. The flow rate was
controlled between 12-15 ml per hour, and ferritin, vitam in Bjj, and
dinitrophenylalanine (DNP-ala) were used as the molecular weight m arkers.
One ml fractions of eluate were collected with a ISCO model 1850 Fraction
Collector and UV-absorbance was m easured with a model UA-5 Absorbance/
Fluorescence Monitor (ISCO, INC.).

6

. Bicarbonate Determination:
BaClg, a t a final concentration of 20 mM, was added into all 1 ml-

fractions from the P-2 column. The white precipitation of Ba(HC g was
0

16
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) 2

monitored by absorbance reading a t a wavelength of 600 nm with a PerkinElm er Lambda 3A UV/VI spectrophotometer.
8

7. Assay of Leukotriene

Dipeptidase Activity:

The reaction m ixture consisted of a mixture of 100 ng synthetic unlabeled
LTD4, tritium labeled LTD4 0.8 pi ( 0.1 ng LTD4, specific activity: 1.8x10*

dpm), and 100 pi enzyme (protein concentration: 27.1-60.6 pg/pl) in a 100
mM NaCl, 5 mM CaClg, 0.1% triton, and 100 mM Mops buffer a t a pH of
7.4. The m ixture was incubated in 37® C w ater bath for 15 to 35 min
depending on which enzymatic activity was being measured. The reaction
was stopped by adding 0.5 ml cold methanol (-20° C). The mixture was then
stored a t -70° C for a t least

8

1

hour prior the lipid extraction.

. Lipid Extraction:
Cold m ethanol was used to stop the reaction and extract the lipid in the

m ixture. The m ixture was centrifuged a t 2,000xg for 30 min a t 4° C. The
su p ern atan t was transferred to a conical centrifuge tube and the residue
was extracted w ith another 0.5 ml methanol. After centrifugation the
supernatants were pooled and evaporated to dryness under vacuum at 40°
C. The samples were stored a t -70° C until HPLC analysis. All glassware
used for the assays was silicone-treated to prevent the adherence of lipids to
the surface, and to minimize loss of leukotreines.

17
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9. RP-HPLC Analysis:
A CIS 5 Tim 100 A nucleosil HPLC column, 4.6 X 250 mm, was used for
reverse-phase HPLC analysis. The solvent used for isocratic eluting
contained acetonitrile, methanol, acetate, and distilled water
(320:200:1:479). Disodium EDAT (0.5%) was added and pH was adjusted to
5.5 w ith ammonium hydroxide. The leukotriene extract was dissolved in
0.15 ml eluting solvent and eluted from the column a t a flow rate of 1.0-1.5
ml/min. The products of [^H] LTD^ metabolism were quantified by the
distribution of tritium counts in the different fractions using an in-line
radioactivity flow detector.

18
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CHAPTERS
RESULTS

1

. LTD dipeptidase inhibitor activity in hum an serum:
4

Previous experiments in our laboratory showed th a t dilution of serum
did not result in a corresponding dilution of LTD^ dipeptidase activity. A
typical experiment using a series of two-fold serum dilutions is shown in
Fig. 5. The highest specific activity was usually observed a t a 1:32 dilution.
This indicates the presence of some type of inhibitory factoHs) in the serum.
2

. Serum fractionation:
The inhibitory factor(s) was successfully separated from the LTD

4

dipeptidase by using an Amicon ultrafiltration system w ith a YM-10
m em brane. As shown in Fig. , the LTD4 dipeptidase activity was increased
6

after removing the inhibitory factor(s) by filtration, and showed an almost
linear decrease in dipeptidase activity with serial dilution. The products of
LTD formed in the presence of a 25-50% ammonium sulfate fraction and a
4

50-75% ammonium sulfate serum fraction are shown in Fig. 7. Based on
the lower am ount of the unidentified metabolite produced by the 50-75%
fraction, this preparation was used for the separated studies. Using the
synthetic LTE as a substrate, it was shown th a t the unknown metabolite
4

was a product of LTE4 metabolism (Fig. 8). There was no dipeptidase
activity in either 0-25% ammonium sulfate fraction or in the 75-100%
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DIPEPTIDASE SPECIFIC ACTIVITY
SERUM DILUTION STUDY
- O - LTD4
SPECIFIC
ACTIVITY
CONVERSION
100

20

I

£

I

I

I

>
t

50

>

eI

1
«

<

I

O

1

1/8
1 /1 6
1 /4
DILUTION (1: undiluted, 6 0 .6 mg/ml)
1/2

1 /3 2

Figure 5. U ntreated serum was 2-fold series diluted with 100 mM
Mops buffer, pH 7.4. The enzyme assay was carried out as described in
M aterials and Methods (M&M) p art 7. HPLC method described in M&M
p a rt and 9 was used to quantify the conversion of leukotrienes. Solid line
shows the LTD^ conversions with the dilution of the untreated serum.
Dotted line shows the specific activities of the untreated serum with the
dilution. The specific activity is expressed as pmol leukotriene converted
per min per mg protein.
8

20

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

AMICON MEMBRANE FILTRATION
HUMAN DIPEPTIDASE ACTIVITY
100

50

g
I

1
«9
fe

1 /2

1

1/4
1/8
DILUTION (1: UNDILUTED)

1/16

1/32

Figure . H um an serum LTD^ dipeptidase activity was separated
from the inhibitory factoKs) by an Amicon M icro-ultrafiltration system
using a YM-10 membrane as described in the part 2 of M&M. Then dilution
and enzyme assay were carried as described in Fig. 5. Solid line shows the
filtered dipeptidase activity. Dotted line shows the untreated serum.
6
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JIIA.

LTD4 CONTROL

B

UTD4

LTD4 INCUBATED W/ 50-75%

LTE4

(NH^)gSO^ PPT. FRACTION
LTD4

LTD4 INCUBATED W/ 25-50%
(NH^)gSO^ PPT. FRACTION

LTD 4

Figure 7. Ammonium sulfate fractionation of serum was carried out
as described in the p a rt 3 of M&M. Different fractions were tested for the
dipeptidase activity. The distribution of radioactivity counts on
chrom atograph was used to m om itor the conversion of LTD^. (a) LTD^
control, (b) LTD was mainly converted to LTE by a dipeptidase activity in
50-75% ammonium sulfate precipitation, (c) LTD was converted to an
unknown metabolite by an enzymatic activity in the 25-50% ammonium
sulfate precipitation fraction.
4

4

4
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Figure . 100 ng LTE was used as the substrate incubting with the
25-50% saturated ammonium sulfate precipitation fraction. Standard LTE^
and metabolized LTE4 were m easured a t a wavelength of 280 nm. (a) LTE4
control, (b) Unknown metabolite with a later retention time after LTE* was
incubated w ith 25-50% saturated ammonium sulfate precipitation fraction.
8

4
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am m onia sulfate supernatant.
3. Optim al conditions for LTD dipeptidase activity:
4

Fig. 9 shows the time course study of the LTD* dipeptidase activity in
the 50-75% saturated ammonium sulfate fraction. Under this assay
condition, over 90% of the synthetic LTD* was converted after 50 m in
incubation. The influence of different cations is shown in Fig. 10. The
enzyme was about 30% inhibited by 20 mM EDTA and 10 mM EGTA, and
was activated by 10 mM Ca^* and 2.9 mM Mn^"^. Fig. 11, 12, and 13 show
th a t optimal activity was obtained with

1

0

0

mM NaCl and 5 mM CaClj,

which both are close to the physiological concentration in hum an serum.
4. Separation of the inhibitory factors) from serum by ultrafiltration:
The Amicon ultrafiltration system with the YM-10 membrane was
used to separate the LTD* dipeptidase inhibitory factor(s) from the serum as
described in m aterials and methods. After lyophilization, the filtrate was
resuspended in a volume of 20 times concentrated (20X). The addition of
the concentrated inhibitor(s) to the dipeptidase assay m ixture resulted in
the inhibition of LTD* dipeptidase action (Table 1).
5. C haracterization of the inhibitor:
The concentrated YM-10 filtrate was incubated a t 95° C for 30 min
and assayed for inhibitory activity. The inhibitory activity was not
destroyed. The concentrated YM-10 filtrate (20X) was stable in 0.3 N
NaOH (20 pi 2 N NaOH in 100 pi concentrated filtrate, 20X), whereas the
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ENZYME: TIME COURSE STUDY
S 0 % -7 5 % AMMONIUM SULFATE PPT.
100

m
tLTD4

I

A -A -

50

o -

LTE4
UNKNOWN

O

0

6
0

50

100

INCUBATION TIME (min)

Figure 9. LTD^ Dipeptidase of hum an serum incubated with LTD^ for
various incubation period. Same assay conditions were used as described in
Fig. 5.
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EFFECT O F IONS ON DIPEPTIDASE
CATIONS AND CHELATORS
100

1
CO

f
LTD4
50

J LTD4
CONVERTED

o

o

4

5
6
7
SAMPLE

8

9

10

Figure 10. Different cations and chelators were added to observe their
effects on the dipeptidase. Standard enzyme assays as described in Fig. 5.
was used. Different cation concentrations were added based on their
physilogical concentrations. 1. Buffer control. . Enzyme control. 3. EDTA
(20 mM). . EGTA (10 mM). 5. Ca^+ (10 mM). . Mg^+ (4 mM). 7. Fe^"
(0.084 mM). . Mn^* (2.9 mM). 9. Zn"+ (0.44 mM).
. Cu"+ (0.071 mM).
2

4

6

8

1

0

26

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

OPTIMAL IONIC CONCENTRATION
— SODIUM CONCENTRATION STUDY
100
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H
S
—+ — LTD4
i
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iH

i
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-A -

LTE4

- O -
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g
6

0

250

500

SODIUM CONCENTRATION (mM)

Figure
. The influence of NaCl concentration on LTD dipeptidas
activity was studied by adding different NaCI concentrations into the
standard enzyme assays.
1

1

4
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OPTIMAL IONIC CONCENTRATION
— CALCIUM CONCENTRATION STUDY
100

m
5

i

- +-

LTD4

—A—

LTE4

- o -

UNKNOWN

3

A

0

5

10

CALCIUM CONCENTRATION (mM)

Figure 12. The influence of CaClg concentration on LTD^ dipeptidase
activity was studied by adding diflferent concentration of Calcium into the
stan d ard enzyme assays.
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OPTIMAL IONIC CONCENTRATION
THE EFFECT OF SODIUM AND CALCIUM
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Figure 13. Optimal condition for dipeptidase activity was achieved by
adding sodium chloride and Calcium chloride into the reaction mixture. 1.
Buffer control. 2. Enzyme control. 3. 100 mM NaCl 4. 5 mM CaClg. 5.
mM N ad + 5 mM CaClg.
1

0

0
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TABLE 1. THE DIPEPTIDASE INHIBITION PROPERTIES
OF YM-10 FILTRATE

W/ YM
SAMPLES

- 1

0

FILTRATE

% OF LTD. CONVERSION

W/O YM-10 FILTRATE
% OF LTD. CONVERSION

17.47

79.90

2

13.91

83.84

3

18.34

83.50

4

21.04

5

17.71

84.86

6

17.47

86.36

1

X±SD,n

=

6

8

6

. 2

0

84.11±2.17%

17.66±2.08%
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Figure 14. The separation of LTD Dipeptidase inhibitor by Bio-Rad
gel P-2 Column was described in part 5 of M&M. (a) Molecular weight
m arkers control: peak , ferritin; peak 2, VitB^g; peak 3, DNP-ala. (b)
C oncentrated inhibitor from YM-10 filtrate ( X). The inhibition was
recovered from 49 to 60 ml with a pH range from to 8.5. (c) Bicarbonate
with the MW m arkers.
4

1

2

0

8
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IDENTIFICATION OF INHIBITOR
COMPARISON OF THE RETENTION TIME
-

pH

ABSORBANCE

9

2 .4 0

o

0
(O

i

1.20

8

1
i

I
0.00

7
45

55

65

ELUTION VOLUMNE (ml)

Figure 15. Comparison of retention time of synthetic bicarbonate and
LTD Dipeptidase Inhibitor from Serum. As described in p art of M&M,
two indicators were mainly measured: pH and carbonate (bicarbonate).
Sohd line: pH of concentrated YM-10 filtrate eluted from P-2 column.
Dotted line: Absorbance of BaCHCOglj precipitation formed by synthetic
bicarbonate eluted from P-2 column and BaClj added.
4

6
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inhibitory activity was destroyed in 0.3 N HCl (20 jil 2N HCl in

1

0

0

pi

concentrated filtrate, 20X). The inhibitory effect was eliminated by treating
with 0.3 N HCl a t either 0"C or a t 65”C for 30 min (Fig. 17).
Concentrated filtrate from the YM-10 m embranes was filtered with
YM-3, YM- , and YC-05 membranes. Inhibitory activity was recovered in
1

the filtrate from each of these membranes which suggested a molecular
weight of less th an 500 (Fig. 16). Elution from the P-2 gel filtration column,
however, suggested a molecular weight of about 800-1000 (Fig. 14B).
6

. Purification of inhibitory factor(s) by gel filtration:
The inhibitor(s) was eluted from a Bio-Rad gel P

- 2

column with a 10

mM NaCl, 10 mM Mops buffer pH a t 7.4. As shown in Fig. 14B, the
inhibitory factorfs) was recovered from the P-2 column in fractions fi*om 49
ml to 60 ml. The retention time of the inhibitory factor(s) from the P-2
column corresponds to a molecular weight around 800-1,000 based on
internal molecular weight m arkers vitam in

(MW 1,355) and DNP-ala

(MW 255) (Fig. 14A). The pH of the 49th ml-60th ml fractions was 8.0-8.4
compared to 7.0-7.4 for all other fractions (Fig. 15). The pH of all
concentrated fractions was adjusted to 7.4 for the enzyme inhibitor assay.
7. Identification of inhibitor(s):
The in h ib ito rs ) was heat stable, acid labile, and resulted in an
increase in pH when concentrated. Based on these observations we
suspected th a t the in h ib ito rs) might be bicarbonate. This did not
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correspond to the expected elution volume from the P-2 column. The
ap parent contradiction was solved when analytical grade sodium
bicarbonate was ru n through the P-2 column and the same retention time
was obtained as th a t of the inhibit activity and high pH of the concentrated
filtrate, 20X (Fig. 14, 15). The bicarbonate elution was qualitatively
m onitored by adding BaCIj resulting in a production of white precipitate.
8

. Inhibitory activities of bicarbonate and other anions:
The effect of different anions is shown in Fig. 18. The inhibitory

activity was found for bicarbonate and phosphate, whereas no inhibition
was observed w ith sulfate or nitrate. Fig. 19 and 20 show th a t the
inhibitory activity of carbonate and phosphate was dose dependent. The
m axim um inhibition caused by bicarbonate (250 mM) was about 50%, while
th a t of the phosphate (400 mM) was 100%.
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INHIBITOR SIZE DETERMINATION
AMICON MEMBRANE YM 1 0 -

05
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0
LTD4
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g
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6

Figure 16. Amicon membranes were used to determine the Molecular
W eight of LTD dipeptidase inhibitor. 100 pi of 20X inhibitor solution
passed different m embranes were added to standard enzyme assays.
Inhibition was observed in all size of membrans used. . Buffer control. 2.
Enzyme control. 3. YM-10. 4. YM-3. 5. YM- .
. YC-05.
4

1

1

6
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INHIBITOR CHARACTERIZATION
2 N HCl TREATMENT
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LTD4
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6

Figure 17. X Inhibitor solution was pretreated with 0.4 N HCl
under heating and non-heating conditions. The inhibitory activity was
elim inated by the acid. 1. Buffer control. 2. Enzyme control. 3. Inhibitor
control. 4. Inhibitor with 0.4 M HCl on ice. 5. Inhibitor is heated a t 65“ C
for 30 m in with presence of 0.4 M HCl. . NaCl control. 7. Salt+inhibitor
control.
2

0

6
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INHIBITION O F DIPEPTIDASE
THE EFFECTS OF ANIONS
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LTD4
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Figure 18. Inhibition of anions on LTD^ dipeptidase activity was
assayed by addeding different anions concentration into standard enzyme
assay. 1. Buffer control. 2. Enzyme control. 3. Bicarbonate (lOOmM). 4.
Phosphate (lOOmM). 5. Sulfate (lOOmM). . N itrate (200mM).
6
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INHIBITION O F DIPEPTIDASE
THE EFFECT OF BICARBONATE
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Figure 19. Different amount of bicarbonate was incubated with 5075% am m onium sulfate saturated precipitation fractionation of hum an
serum. A 50% inhibition was observed when 250 mM bicarbonate was
added.
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INHIBITION O F DIPEPTIDASE
THE EFFECT OF PHOSPHATE
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Figure 20. Different amount of phosphate was incubated with 5075% ammonium sulfate saturated precipitation fractionation, A 100%
inhibition was observed when 400 mm phosphate was added.
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CHAPTER 4
DISCUSSION

The peptidyl leukotrienes of the 5-lipoxygenase pathway of
arachidonic acid metabolism have been identified as the active ingredients
of the substances collectively known as slow-reacting substance of
anaphylaxis (SRS-A). The leukotrienes rapidly gained substantial attention
w hen the potency of their biological activities on certain cells and organs
were found to exceed th a t of many traditional autocoids such as histam ine,
catecholamines, kinins, and prostaglandins ( ). Of particular importance is
8

the action of the leukotrienes on the pathological processes of allergic
reactions, endotoxemias, tissue injury, and inflammatory responses.
Identification and characterization of the receptors of leukotrienes and their
n atu ral and synthetic inhibitors have been extensively studied (18, 26, 35,
45, 55, 60, 63). Such studies were undertaken to try to develop specific
pharm aceutical agents which may prevent, moderate, or reverse
leukotriene-dependent reactions, and to use such therapeutic reagents to
tre a t leukotriene related diseases.
LTD dipeptidase is the enzyme which converts the most active
4

leukotriene, LTD^, to the least active form, LTE^. The biological activity of
LTD has been reported to be 25 to 100 times higher than th a t of LTE (19,
4

4

48, 58). It is probable, therefore, th a t the nature and intensity of the
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response would be influenced by the relative concentrations of LTC*, LTD ,
4

and LTE which, in turn, could be determined by the relative rates of
4

metabolism of LTC* to LTD4 and LTD4 to LTE4. The m arked increase in the
specific activity of the LTD dipeptidase in the serum dilution experiments
4

(Fig. 5) suggested th a t the enzyme activity is determ ined by inhibitor
concentration ra th e r th an enzyme concentration. Since the first dipeptidase
was isolated from porcine kidney in 1969 (9), enzymes from several different
species and tissues have been isolated and characterized (10, 11, 17, 22, 2729). Likewise, several dipeptidase inhibitors have been also studied.
Generally, bestatin (

1

0

,

1

1

, 40) and D-penicillamine (24) cause

noncompetitive inhibition of dipeptidase, whereas cilastatin (27),
dithiothreitol, an d chloroacetyldehydrophenylalanine are competitive
inhibitors of the enzyme (10, 11). Inorganic phosphate, ATP, ADP, and
AMP have also been reported to inhibit the dipeptidase (9). Some divalent
m etal ions m ay also play im portant roles in dipeptidase metabolism, since
the m etal chelator, o-phenanthroline, can inhibit the dipeptidase activity,
and th e inhibition can be reversed by adding divalent m etal ions such as
Co^"^, Mn^*, and Zn^\ This also suggests th at the dipeptidase from certain
sources may be a metalloenzyme (36). None of these dipeptidase inhibitors
seems a likely candidate for the natural inhibitor in serum (Table. 2)
The inhibition of the dipeptidase in undiluted hum an serum was suggested
by th e observations of Roller et al (28). They assayed the y-transpeptidase
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TABLE 2. COMPARISON OF THE LTD^ DIPEPTIDASE
SESENSITIVITY TO BESTATIN AND CILASTATIN

DIPEPTIDAES

INHIBITOR

CONCENTRATION (mM)

HUMAN SERUM BESTATIN

CILASTATIN

SHEEP LUNG'*°* BESTATIN

CILASTATIN

INHIBITION

0.001

0

0.005

0

0.05

50%

0.001

0

0.005

0

0.05

50%

0.001

6%

0.005

41%

0.001

48%

0.005

100%
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in undiluted hum an serum but used a 1:50 dilution for the dipeptidase
assay. A sim ilar phenomenon was observed by Foster and his coworkers
(17) in th eir studies of LTC^ metabolism in the anesthetized rat.
Intravenously injected LTC was rapidly converted to LTD , while the
4

4

conversion of LTD to LTE was considerably slower. The results of our
4

4

studies suggested to us th a t carbonate (bicarbonate) is responsible for the
LTD4 dipeptidase inhibitory activity in normal serum. The dipeptidase

activity did not decrease until the serum was diluted 32 fold. After
filtration with a YM

- 1

0

membrane, the bicarbonate and phosphate were

removed in the filtrate, and the retained enzyme activity decreased with
dilution as expected. Inhibitions caused by bicarbonate and phosphate are
dose dependent. Bicarbonate is a more likely the m ain inhibitor in serum
th an phosphate because of its higher physiological concentration (25 mM,
for bicarbonate, vs. 2 mM for phosphate). The finding th a t inorganic
phosphate inhibits hum an serum LTD4 dipeptidase is consistent with the
results of Campbell and his coworkers who identified inorganic phosphate
as an inhibitor for porcine renal dipeptidase (9). Our studies represent the
first tim e th a t bicarbonate was identified as a natural inhibitor of LTD4
dipeptidase in hum an serum. The experiments in our lab also showed th at
LTD4 dipeptidase activity in hum an serum is less sensitive than previously

reported inhibitors , cilastatin and bestatin (Table. 2). Additionally, the
dipeptidase activity in hum an serum is not dependent on divalent metal
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ions, and was not specifically activated by Co^*, M n -\ and Zn^\
Furtherm ore it was interesting to find th at higher concentrations of
divalent ions (5mM), which can precipitate bicarbonate, would increase the
dipeptidase activity. Addition of the chelator, EDTA, restores the inhibitory
effect. These results suggest th at it was the depletion of bicarbonate by the
divalent ions which increased the dipeptidase activity in hum an serum
ra th e r th an a stim ulation of enzymatic activity.
Asthm a is a disease characterized by episodic bronchoconstriction,
hypersecretion of mucus, and inflammation of airways. It was estim ated
th a t approxim ately five percent of adults and seven to ten percent of
children in the United States have the disorder (56). Evidence suggests
th a t the 5-lipoxygease pathway metabolites of arachidonic acid, especially
the peptidyl leukotrienes (LTD , LTC , LTE ), have a very im portant role in
4

4

4

m ediating the physiologic events in asthma. Schwartzberg and his
colleagues observed a 50-fold elevation of LTC levels in children with an
4

acute asthm a attacks (52-54). An increased level of leukotrienes was found
in brochoalveolar lavage fluid from atopic asthm atics (62). Radeau and his
coworkers reported an enhanced arachidonic acid metabolism in asthm a
patien ts (43). The elevated level of leukotrienes may be a result of either
increased release from the inflammatory cells (eosinophiles, macrophage
etc.) or inhibition of leukotriene degradation by the leukotriene metabolizing
enzymes or both. O ur experimental data showed th a t bicarbonate is one of
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the inhibitory factors in hum an serum. Because it is inhibitory a t
physiological concentrations, it may play a major regulatory role in
regulating the LTD dipeptidase activity in hum an serum.
4

Bicarbonate is the major component of the carbonic/bicarbonate
buffering system in hum an circulation. The system is defined by the
Henderson-Hasselbach equation: pH =

6

. 1

+ log ([HCO MH CO ]). Mainly
3

2

3

two organs and one enzyme are involved in regulating the carbonic
acid/bicarbonate buffer system. The carbon dioxide produced by aerobic
metabolism of different tissues is transported to the lung and exhaled. The
rate of respiration and COg/Og exchange capacity of the lung is one method
contributing to the regulation this system. The kidneys are the second
contributor in regulating the buffer system. The bicarbonate is reabsorbed
w hen its serum concentration is less than 26 mEq/L, and it is excreted in
the urine if its serum concentration is greater th an 26 mEq/L. Bicarbonate
is reabsorbed in the proximal and distal tubule, with 85 to 90 percent
reabsorbed proximally, and 10 to 15 per cent distally. The enzyme involved
in regulating this buffer system is carbonic anhydrase. This enzyme exists
a t a high concentration in red blood cells, and on the luminal surface of
proximal tubule cells in kidneys. It catalyzes the reversible reaction: COg +
HgO = HgCOa =

4

.

HCO3

. The first reaction rate, catalyzed by carbonic

anhydrase, is several hundred times higher th an th a t without the enzyme.
The second reaction occurs rapidly without an enzyme. The COg produced
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by th e aerobic metabolic process diffuses from cells into tissue capillaries
and enters red blood cells. The carbonic anhydrase in the red blood cells
converts the COg into HCO . The newly produced bicarbonate diffuses into
3

plasm a because cell membranes are much more permeable to negatively
charged anions (e.g. HCO3*, Cl ) than to positively charged cations (e.g. K*,
H^). The electrostatic difference across the cell membrane created by the
movement of HCO can be neutralized by the movement of Cl into the red
3

blood cells, which is called the chloride shift". This is the major source of
bicarbonate for the carbonic acid/bicarbonate buffer system. The reverse
reaction is carried out when bicarbonate is reabsorbed in the kidney by the
carbonic anhydrase on the surface of proximal tubule cells. Under normal
physiological conditions, when a fixed acid is produced in extracellular
circulation, it can be buffered by bicarbonate. The COg produced is exhaled
from lung. When an airway obstruction happens, the Og/COg exchange is
partially or completely dysfunctional, the COg produced by the hum an body
will be retained in the tissue capillaries. The retained COg may accelerate
the enzymatic conversion to bicarbonate, which is catalyzed by carbonic
anhydrase. This study suggests th at increased bicarbonate levels might
inhibit the LTD dipeptidase activity, causing a higher concentration of the
4

more biologically active leukotrienes. The elevated LTD4 may enhance the
inflam m atory process, mediate the immediate hypersensitivity reaction, and
cause more severe clinical symptoms and manifestations. Previous
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researchers have also shown th at there are LTC and LTD receptors on the
4

4

surface of hum an red blood cells (18). No physiological functions of these
receptors have been identified, and it has been confirmed th a t there are no
leukotriene metabolizing enzymes in the red blood cells. It would be
interesting to determ ine the effect of LTD on carbonate metabolism in
4

erythrocytes. U nder asthm atic conditions, bicarbonate levels in the blood
should increase because of oxygen deprivation. This may result in increased
COg and HCO3. and consequently decreased detoxification of LTD by serum
4

dipeptidase. Modulating the effects of leukotriene may be proposed as
follows. At elevated levels, leukotrienes may bind to the receptors on red
blood cells. This binding may result in the generation of a second
m essenger, such as cAMP, which would modulate and ultim ately inhibite
the activity of carbonic anhydrase. Decreased carbonic anhydrase activity
would result in decreased bicarbonate levels, leading to increased
di peptidase activity. As leukotriene levels fall on detoxification by
dipeptidase, decreased generation of the second messenger would occur,
carbonic anhydrase activity would increase and serum bicarbonate levels
would retu rn to normal. These processes would be initiated by the
obstruction and relief of the obstruction of the airways. The discovery of a
possible role for bicarbonate as the inhibitor of leukotriene metabolism may
lead to the development of new therapeutic agents in treating leukotriene
associated diseases, especially anti-asthm a drugs.
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The major phosphate stores in hum ans reside intracellularly in cell
cytoplasm. The organic phosphate is incorporated into lipid as
phospholipids which compose the cell membranes. Phosphorous is mainly
found as a bone component and exists at relativly low levels as phosphate
in the extracellular circulation. A phosphate buffering system also plays a
m odest role in regulating the pH of blood. Three buffer pairs, H^PO/
/H PO , HPO^^ /HgPO^, and PO/VHPO^^', could potentially be formed.
3

4

U nder the physiological conditions a t pH 7.4, the HPO^^VHgPO/ system with
a pK of

6

. 8

is most im portant. At pH 7.4, there will be four molecules of

HPO^^ for every molecule of H^PO/. Experimental data indicated th a t
inhibition by phosphate occurs a t a concentration almost

2

0

times higher

th a n norm al physiological levels (2 mM). This suggests th a t the phosphate
inhibition of LTD4 dipeptidase may play a minor part in regulating the
leukotriene levels in serum, except under extreme conditions. High
concentrations of intracellular phosphate can be released into a lesion, and
could cause a lim ited and localized inhibitory effects. As dem onstrated by
Campbell and his coworkers (9), ATP, ADP, and AMP showed some
inhibition in hog renal dipeptidase. The phosphate groups on the nucleotide
may explain the inhibition, and the adenosine with most phosphate residues
causes the stronger inhibition, such that, ATP is more inhibitory th an ADP
(ATP>ADP>AMP). F u rth er research may be carried out to reveal the
physiologic functions of intracellular phosphate, organic phosphate of
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phospholipids, and phosphorous in bone, in the regulation of leukotriene
m etabolism.
An unknown leukotriene metabolite was recovered when the 25-50%
am m onium sulfate precipitated hum an serum was incubated with LTD^ or
LTE (Fig. 7, ). Our experimental data demonstrated this unknown
4

8

m etabolite to be enzymatically produced from LTE4. Reverse phase HPLC
analysis showed the retention time of the unknown metabolite is about

3

- 4

m in la te r than th a t of LTE4. This separation using a reverse phase is based
on both of the polarity and size of the compound. This indicates th a t the
unknow n metabolite is less polar and perhaps has a relatively lower
m olecular weight than th at of LTE4. Previous studies showed LTE4 can be
converted into several different metabolites.
Acétylation of LTE4 by acetylase in liver and kidney converts LTE4 to
N-acetyl-LTE* (5). This compound is mainly found in the bile and urine.
HPLC analysis using different solvent systems showed this metabolite had
an earlier elution time, which indicates the compound has a higher polarity
th an th a t of LTE4. LTF4 is derived from LTE4 by conjugating LTE4 and yglutam yl amino acids (2). The reaction is achieved by incubating LTE4 with
y-glutamyl transpeptidase and glutathione. HPLC analysis showed the
compound has a very high polarity and a very early retention time,
compared to that of LTE4.
LTG4 is the derivative of a transamination reaction catalyzed by
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cysteine conjugate aminotransferase (59). The enzyme is found in kidney
and liver, but not in the lung or leukocytes. HPLC analysis showed a much
later retention time of the compound compared to th a t of LTE4.
O ther LTE metabolites include co-hydroxy LTE (4), LTE^ sulfoxide
4

and

6

4

-trans LTB* (31). All these compounds have higher polarity th an th at

of LTE and can be excluded. Determination of the chemical structure and
4

physiological functions of the unknown metabolite could be very crucial in
studying the metabolism of peptidyl leukotrienes. This metabolite could be
a completely inactivated form of the biologically active peptidyl leukotrienes.
F u rth e r characterization of the unknown metabolite is currently in
progress.
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CHAPTER 5
SUMMARY

Peptidyl leukotrienes are a group of biological active metabolites from
the 5-lipoxygenase pathway of arachidonic acid. The rate of degradation of
the leukotrienes is controlled by their specific metabolic enzymes as well as
the enzyme inhibitors. Isolation, identification and characterization of
n a tu ra l and synthetic inhibitors may provide a novel direction in preventing
and treatin g some leukotriene-associated disease. Towards this goal,
several results achieved in this study are as follow;
1

. Bicarbonate was isolated and identified as the major inhibitory

factor of LTD* dipeptidase in human serum, LTD* dipeptidase activity from
hu m an serum was 50% inhibited in 250 mM bicarbonate.
2. Phosphate was the other leukotriene D* dipeptidase inhibitor
which was found in serum. It may play a modest part of the inhibition as
phosphate levels needed for inhibition are almost

2

0

times higher th an th at

of the physiological condition.
3

. The serum LTD* dipeptidase activity was fractionated with

am m onium sulfate. It was found th at the dipeptidase activity was in the
50-75% am m onium sulfate precipitation fraction. The optimal enzymatic
activity was obtained a t pH 7.4 with 5 mM CaClg, 100 mM NaCl in the
assay m ixture.
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4.

An unknown metabolite of LTE was formed when either LTD or
4

LTE was incubated with the 25-50% ammonia sulfate precipitated fraction
4

of serum . Reverse phase HPLC analysis indicates the unknown leukotriene
m etabolite may have a lower molecular weight and polarity than th a t of
LTE4.
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